Antibody drugs are now widely accepted in companion animal health. 272BIO is developing a pipeline of VHH based therapeutic and prophylactic drug to address complex diseases at affordable prices for both developers and customers. The flexibility and modularity of VHH, combined with their suitability to be produced across many different microbial expression systems make them highly suitable for the development of bi- and multi-valent drugs targeting different pathophysiological pathways.
272BIO is making use of the advantages of VHH to develop innovative second-generation treatments for complex diseases including canine atopic dermatitis, osteoarthritis, oncology etc.
A key goal for 272BIO is to develop VHH antibody drugs to transform the lives of patients by addressing the different drivers of disease to result in superior clinical efficacy and better disease control. Development costs, modest market sizes and high drug prices represent barriers to entry for animal health companies, prescribers and pet-parents as well. To overcome these hurdles necessitates the use of expression and manufacturing processes suitable for the challenges of animal health
The experienced team of seasoned antibody scientists can also assist start up biotech and animal health companies in designing and driving their discovery and development phases for their products.